In a report released today, Gena Wang from Barclays maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $45.00. The company’s shares closed yesterday at $25.64.
Wang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and Vertex Pharmaceuticals. According to TipRanks, Wang has an average return of 9.1% and a 45.66% success rate on recommended stocks.
4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.14.
Based on 4D Molecular Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $32.28 million. In comparison, last year the company earned a revenue of $1.25 million and had a GAAP net loss of $27.38 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
4D Molecular Therapeutics (FDMT) Company Description:
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
Read More on FDMT:
- 4D Molecular price target raised to $40 from $35 at RBC Capital
- 4D Molecular initiated with an Overweight at Barclays
- 4D Molecular assumed with a Buy at Jefferies
- 4D Molecular price target lowered to $63 from $70 at BMO Capital
- 4D Molecular announce update on regulatory interactions, development for 4D-710
